Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
152.94
+0.33 (0.22%)
At close: May 23, 2025, 4:00 PM
152.94
0.00 (0.00%)
After-hours: May 23, 2025, 7:59 PM EDT
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 29, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
$646,857
Profits / Employee
$157,929
Market Cap
367.98B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Jan 1, 2023 | 152,700 | 11,000 | 7.76% |
| Jan 2, 2022 | 141,700 | 7,200 | 5.35% |
| Jan 3, 2021 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
JNJ News
- 1 day ago - FDA Panel Reiterates the Cancer Risks of Talc - Business Wire
- 3 days ago - Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference - Business Wire
- 3 days ago - Forget About Dividend Yield, Do This Instead - Seeking Alpha
- 4 days ago - U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma - PRNewsWire
- 4 days ago - Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference - Seeking Alpha
- 4 days ago - Dean Omar Branham Shirley Recognized Twice Among ALM's 2024 Top 100 Verdicts - Business Wire
- 5 days ago - Moody's U.S. Debt Downgrade: Stocks Poised To Benefit - Seeking Alpha
- 6 days ago - Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson's Biosense Webster Medical Technology Unit - Business Wire